The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals?
Open accessAbstract
The concept of antimicrobial peptides (AMPs) as potent pharmaceuticals is firmly established in the literature, and most research articles on this topic conclude by stating that AMPs represent promising therapeutic agents against bacterial and fungal agents. Indeed, early research in this field showed that AMPs were diverse in nature, had high activities with low minimal inhibitory concentrations, had broad spectrums of activity against bacterial, fungal and viral pathogens, and could easily be manipulated to alter their specificities, reduce their cytotoxicities and increase their antimicrobial activities. Unfortunately, commercial development of these peptides, for even the simplest of applications, has been very limited. With some peptides there are obstacles with their manufacture, in vivo efficacy and in vivo retention. More recently, the focus has shifted. Contemporary research now uses a more sophisticated approach to develop AMPs that surmount many of these prior obstacles. AMP mimetics, hybrid AMPs, AMP congeners, cyclotides and stabilised AMPs, AMP conjugates and immobilised AMPs have all emerged with selective or ‘targeted’ antimicrobial activities, improved retention, or unique abilities that allow them to bind to medical or industrial surfaces. These groups of new peptides have creative medical and industrial application potentials to treat antibiotic-resistant bacterial infections and septic shock, to preserve food or to sanitise surfaces both in vitro and in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?
Brogden, K. A. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1098 · Cited by 5,829
Self-citationAntimicrobial and host-defense peptides as new anti-infective therapeutic strategies
Hancock, R. E. W., & Sahl, H.-G. (2006) · Nature Biotechnology · doi:10.1038/nbt1267 · Cited by 4,208
Futaki, S., Suzuki, T., Ohashi, W., Yagami, T., Tanaka, S., Ueda, K., & Sugiura, Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007540200 · Cited by 1,662
Mammalian defensins in the antimicrobial immune response
Selsted, M. E., & Ouellette, A. J. (2005) · Nature Immunology · doi:10.1038/ni1206 · Cited by 1,203
Antibacterial peptides for therapeutic use: obstacles and realistic outlook
MARR, A., GOODERHAM, W., & HANCOCK, R. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.04.006 · Cited by 1,051
Covalent immobilization of antimicrobial peptides (AMPs) onto biomaterial surfaces
Costa, F., Carvalho, I. F., Montelaro, R. C., Gomes, P., & Martins, M. C. L. (2011) · Acta Biomaterialia · doi:10.1016/j.actbio.2010.11.005 · Cited by 627
Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein
Larrick, J. W., Hirata, M., Balint, R. F., Lee, J., Zhong, J., & Wright, S. C. (1995) · Infection and Immunity · doi:10.1128/iai.63.4.1291-1297.1995 · Cited by 573
Yang, D., Biragyn, A., Hoover, D. M., Lubkowski, J., & Oppenheim, J. J. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104603 · Cited by 572
Tam, J. P., Lu, Y.-A., Yang, J.-L., & Chiu, K.-W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.8913 · Cited by 487
Reduction of disulphide bonds unmasks potent antimicrobial activity of human β-defensin 1
Schroeder, B. O., Wu, Z., Nuding, S., Groscurth, S., Marcinowski, M., Beisner, J., Buchner, J., Schaller, M., Stange, E. F., & Wehkamp, J. (2011) · Nature · doi:10.1038/nature09674 · Cited by 457
Cited by
Prevention of Intravascular Catheter-Related Infections
(2021) · Indian Journal of Continuing Nursing Education · doi:10.4103/2230-7354.320831 · Cited by 855
Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics
Murugaiyan, J., Kumar, P. A., Rao, G. S., Iskandar, K., Hawser, S., Hays, J. P., Mohsen, Y., Adukkadukkam, S., Awuah, W. A., Jose, R. A. M., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11020200 · Cited by 567
Gan, B. H., Gaynord, J., Rowe, S. M., Deingruber, T., & Spring, D. R. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00729c · Cited by 511
Antimicrobial Peptides and Their Therapeutic Potential for Bacterial Skin Infections and Wounds
Pfalzgraff, A., Brandenburg, K., & Weindl, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00281 · Cited by 481
Combating Multidrug‐Resistant Bacteria: Current Strategies for the Discovery of Novel Antibacterials
O'Connell, K. M. G., Hodgkinson, J. T., Sore, H. F., Welch, M., Salmond, G. P. C., & Spring, D. R. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201209979 · Cited by 435
Metadata
- Authors
- Brogden, N. K., & Brogden, K. A.
- Venue
- International Journal of Antimicrobial Agents
- Publisher
- Elsevier BV
- Published
- 2011-07
- Volume
- 38
- Issue
- 3
- Pages
- 217-25
- ISSN
- 0924-8579 (ISSN-L)
- OpenAlex
- W2151084977
- Cited by
- 300
- References
- 107
- FWCI
- 20.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals? https://app.cochat.ai/papers/10.1016/j.ijantimicag.2011.05.004
- The paper
- Brogden, N. K., & Brogden, K. A. (2011). Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals? International Journal of Antimicrobial Agents. https://doi.org/10.1016/j.ijantimicag.2011.05.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
